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The regulatory circuit controlling cellular protein phosphatase-1 (PP1), an abundant group of Ser/Thr
phosphatases, involves phosphorylation of PP1-specific inhibitor proteins. Malfunctions of these inhibitory
proteins have been linked to a variety of diseases, including cardiovascular disease and cancer. Upon
phosphorylation at Thr38, the 17-kDa PP1 inhibitor protein, CPI-17, selectively inhibits a specific form of PP1,
myosin light chain phosphatase (MLCP), which transduces multiple kinase signals into the phosphorylation of
myosin-II and other proteins. Here, the mechanisms underlying PP1 inhibition, and the kinase/PP1 crosstalk
mediated by CPI-17 and its related proteins, PHI, KEPI, and GBPI, are discussed.
Introduction
The reciprocal activities of protein kinases and phosphatases determine protein phosphorylation levels
in cells. PP11 dephosphorylates phospho-Ser/Thr residues of proteins, to regulate multiple signal pathways at
various cellular loci (1-3). Cellular PP1 is associated with PP1 regulatory protein/subunits at their PP1-binding
site, known as the RVXF motif. The binding of PP1 regulatory proteins thus confers substrate specificity and
localization on cellular PP1. Nearly 100 polypeptides have been identified as PP1 regulatory proteins and these
account for the wide spectrum of PP1 function (1-3). In addition, eukaryotic cells express several PP1 inhibitor
proteins that play important roles in regulating cellular PP1. The first generation of PP1 inhibitor proteins
involves inhibitor-1, inhibitor-2, DARPP32 and NIPP-1, which potently inhibit the free catalytic subunit of PP1,
but these inhibitor proteins were much less potent toward purified PP1 holoenzymes, MLCP and the glycogenbound PP1. Therefore, cellular PP1 holoenzymes were thought to undergo subunit dissociation prior to the
inhibition of PP1 by the inhibitor proteins (1,2). However, the number of PP1 holoenzymes that do undergo
subunit dissociation in cells remains unclear.
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MLCP is a trimeric PP1 holoenzyme, consisting of a PP1∂ isoform and a regulatory complex of MYPT1
(a.k.a. MBS, M110) regulatory and M21 accessory subunits that govern myosin-II phosphorylation (4). MYPT1
and PP1 bind through the MYPT1 KVKF segment, as well as its 8-repeat ankyrin motif at the N-terminal
domain (5). Binding of the N-terminal 300-residue domain of MYPT1 is sufficient to allosterically regulate PP1
activity.
The MYPT1 C-terminal domain directly binds to substrates, including myosin and
ezrin/radixin/moesin (4). MLCP activity is tightly regulated in response to various signals. For example, in
smooth muscle, activation of the G-protein coupled receptor inhibits MLCP resulting in increased Ca2+
sensitivity of myosin phosphorylation and contraction, whereas cyclic nucleotide signals can activate MLCP to
induce smooth muscle relaxation (6). MLCP inhibition occurs upon MYPT1 phosphorylation at Thr696 and
Thr853 (4). On the other hand, cGMP-K can activate MLCP (7). These regulatory signals are MYPT1 isoformdependent (8), suggesting an important role for MYPT1 in MLCP regulation. In addition, we identified the
MLCP inhibitor protein, named CPI-17, which transduces G-protein signals into MLCP inhibition (9,10). Based
on sequence similarity, three CPI-17 homologues, PHI, KEPI and GBPI, in the human genome were
characterized as PP1 inhibitors (11-13). Each CPI-17 family member carries a PP1 holoenzyme inhibitory
(PHIN) domain, where the sequences are >41 % identical to CPI-17 (Fig. 1A). Indeed, all CPI-17 family
members potently inhibit MLCP activity, which suggests new avenues for PP1 holoenzyme inhibition. This
Minireview will focus on CPI-17 and its homologues, whose amino acid sequences differ significantly from
other PP1 inhibitor proteins, highlight critical findings from CPI-17 studies, and discuss the role of other CPI-17
family members in regulating PP1 activity.
Structure and function of CPI-17
Amino acid sequence of CPI-17: The CPI-17 gene (PPP1R14A, chromosome 19) encodes a 147-residue
polypeptide where >85 % of the amino acids are identical within mammals (10) (Fig. 1A). A splice variant of
CPI-17 (CPI-17β) lacking exon 2 exists in human smooth muscle cells, although whether this form is
physiologically relevant is not known (see subsequent section) (14). Zebrafish express a similar gene, although
to which CPI-17 family member this gene product is functionally related is unclear. No homologous genes have
been detected in fruit fly, nematode, and yeast genes, suggesting that the CPI-17 family emerged at a late stage
in evolution. Phosphorylation of CPI-17 at Thr38 is necessary and sufficient to convert the protein into a potent
MLCP inhibitor (9,10). No homology is detected between the CPI-17 family and other classes of PP1 inhibitors,
such as inhibitor-1 and inhibitor-2, even though phosphorylation is also involved in the function of most other
PP1 inhibitor proteins. The CPI-17 structure has three domains: N- and C-terminal tails and the central 86residue PHIN domain between residues 35 to 120 (Fig. 1A) (15). The sequence surrounding the inhibitory
phosphorylation site characterizes the CPI-17 family, and is pseudo palindromic, (basic)-(hydrophobic)-Thr(hydrophobic)-(basic) (16). Tyr41, Asp42 and Arg43 of CPI-17 are necessary for the inhibitory activity, and
also conserved among CPI-17 family members (15). Substitution of Ala at CPI-17 Tyr41 accelerates phosphoThr38 dephosphorylation, the significance of which will be discussed (15). In contrast to the PHIN domain,
both the N- and C-terminal tail domains are unique for each CPI-17 family member. The other CPI-17 family
members do possess the putative PP1 binding RVXF motif, which is located at the N-terminal tails of PHI,
KEPI and GBPI (Fig. 1A, green box) (11-13).
3D structure of CPI-17: Solution NMR studies revealed the 3D structure of unphosphorylated and phosphoCPI-17 PHIN domains (16). The structure of the CPI-17 PHIN domain consists of a loop structure
encompassing the phosphorylation site Thr38 (P-loop), followed by a four-helix bundle that stabilizes the P-loop
structure (shown in Fig. 1A, bottom) (16). Fig. 2 shows the 3D structural models of unphosphorylated and
phospho-CPI-17. In the unphosphorylated form, two paired A/D and B/C helices form a V shape structure with
the P-loop situated between the paired helices (Fig. 2, left). Upon Thr38 phosphorylation, the P-loop becomes
more solvent exposed, and in doing so, generates torque in the A-helix. This twisting of the A-helix rolls the AB loop up to align the B/C helices in parallel with the A/D helices (Fig. 2, center). The newly aligned four
helices are then stabilized through a hydrophobic core that is created by the rearrangement. The P-loop of
phospho-CPI-17 is now displayed on the molecular surface, tethered by Tyr41. Presumably, the anchoring
function of Tyr41 is necessary to prevent dephosphorylation of the MLCP active site. The phosphate group at
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Thr38 cannot be replaced with Asp, which causes P-loop dislocation with a minimal increase in inhibitory
potency, or with Glu, which distorts the overall structure. Furthermore, substitution of a cysteine-derived
sulphonic acid side chain at Thr38 cannot mimic phosphorylation. Thus, the phosphate group seems to play a
specific role for CPI-17’s potent inhibitory activity beyond only being a trigger of conformational change. The
splice variant CPI-17β retains the P-loop and the A/D-helix pair, although whether this isoform can inhibit PP1
or functions as a dominant negative form in the cell is not known. Based on the sequence similarity in the PHIN
domain, the structural topology and as such the function is likely conserved for CPI-17 family members.
Selective inhibition of MLCP by phospho-CPI-17: Phospho-CPI-17 selectively inhibits the MLCP complex
with an IC50 value of around 1 nM (17,18). How then can CPI-17 recognize only the PP1 associated with
MYPT1 among nearly one hundred other PP1 holoenzymes that exist in cells? Fig. 2 illustrates our current
model for the selective inhibition of MLCP by phospho-CPI-17. PP1 associated with MYPT1 is unable to
hydrolyze the phospho-Thr38 of CPI-17, so that phospho-CPI-17 forms a stable complex with MLCP (Fig. 2,
left). On the other hand, other PP1 holoenzymes are able to dephosphorylate phospho-CPI-17 and neutralize its
inhibitory potency. Simply put, the PP1 regulatory subunit determines whether phospho-CPI-17 is an inhibitor
or substrate of PP1. A kinetic analysis suggests a mixed inhibition of MLCP is induced by phospho-CPI-17,
with Ki and Ki’ values of 1.9 nM and 5.1 nM, respectively (17). Indeed, computer modeling predicts a direct
contact between phospho-CPI-17 and MYPT1 (Fig. 2, right), which may account for CPI-17’s specific
inhibition of MLCP (16). Fig. 1B illustrates the electrostatic surface potential of phospho-CPI-17 and the
predicted maps for other CPI-17 homologues calculated from sequence alignments. The docking surface of
CPI-17 (Fig. 1B left) consists of positively charged residues surrounding an acidic island of phospho-Thr38
(cyan arrow). The positively charged regions around phospho-Thr38 seem to complement the acidic cluster
formed by PP1 and the MYPT1 ankyrin repeat domain (5). The pattern of surface potential varies within the
CPI-17 family, whereas the negative charge dominates in models of PHI-1 and KEPI structures, and the positive
charge is clustered at the edge of GBPI (Fig. 1B). The differences in the structure of the docking surface suggest
that each CPI-17 homologue selectively controls a specific subset of target PP1 holoenzymes and cellular
events.
Role of CPI-17 in cell signaling
Kinases and phosphatases regulating CPI-17: Multiple kinases and phosphatases are involved in regulating
CPI-17 phosphorylation. In smooth muscle, CPI-17 phosphorylation occurs in response to agonist stimulation
through activation of PKC, ROCK and ILK (19,20). Indeed, PKC α and δ are the dominant kinases for CPI-17
in pig aorta smooth muscle extracts (21). Also, CPI-17 binds to the regulatory domain of PKC isoforms,
including α, ε, λ, ζ, and µ (22). Zipper-interacting kinase and p21-activated kinase are also known to directly
phosphorylate isolated CPI-17 at Thr38 (23,24). Thus, CPI-17 is expected to function as a hub of multiple
kinase signals that control MLCP activity. For example, α1-adrenergic receptor stimulation produces bi-phasic
phosphorylation of CPI-17 through the sequential activation of PKC and ROCK in smooth muscle (25). The Gprotein coupled receptor-induced rapid activation of Ca2+-dependent PKC elicits acute CPI-17 phosphorylation,
causing MLCP inhibition, which amplifies the Ca2+-calmodulin-dependent myosin light chain kinase signal.
Following Ca2+ withdrawal, the delayed and sustained activation of ROCK maintains CPI-17 and MYPT1
phosphorylation, causing tonic smooth muscle contraction (25). Thus, the combination of kinase signals confers
the profile of smooth muscle force generation through CPI-17 phosphorylation. CPI-17 phosphorylation
reversibly declines in response to elevated cAMP/cGMP levels (26), which attenuate PKC and ROCK signals
(27). In addition, treatment with a cGMP analog possibly activates unidentified phosphatase(s) that can
dephosphorylate CPI-17 (28). In our model, CPI-17 is dephosphorylated by such “other” PP1 complexes (Fig.
2) (18). In addition, purified protein phosphatase 2A and 2C are capable of dephosphorylating CPI-17 (29),
suggesting the possible involvement of multiple phosphatases in regulating CPI-17 phosphorylation.
Interestingly, PKA is known to phosphorylate and activate PP2A in brain (30), so that CPI-17
dephosphorylation could occur through cAMP/cGMP-activated PP2A. It should be noted that high activity of
CPI-17 phosphatase(s) may explain why CPI-17 phosphorylation cannot be detected in thromboxane A2-
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stimulated cerebral artery from normal rat (31) or phenylephrine-stimulated mesentery arteries from genetically
hypertensive rats (32). In addition to Thr38, purified PKC also phosphorylates Ser12 at the CPI-17 N-terminal
tail, while CaMKII preferentially phosphorylates Ser130 at the CPI-17 C-terminal tail (9,33). CPI-17
phosphorylation at Ser128 was also detected in brain tissue extracts (33). However, the physiological relevance
of this additional phosphorylation at both tails remains to be investigated. The possibility that these sites are
involved in regulating other target subsets, as reported for the phosphorylation of DARPP32 at Thr34 and Thr75
that induces the inhibition of PP1 and PKA, respectively (34), cannot be discounted, however.
Expression of CPI-17: CPI-17 is predominantly expressed in mature smooth muscle (10), and higher levels are
present in tonic muscles, such as arteries (at 7 µM), compared with phasic muscles, such as ileum, bladder and
vas deferens (at 0.8 µM), or cells in neointimal lesions (35,36). CPI-17 is also expressed in embryonic cardiac
muscle where smooth-muscle marker proteins are expressed, but its expression disappears in adult tissue (36).
Platelet, neuron, endothelium and epithelium also express CPI-17, whose roles in these tissues will be discussed
(35-37). Accumulating evidence suggests a correlation between the CPI-17 expression level and the extent of
PKC-mediated Ca2+ sensitized force. Selective permeabilization of smooth muscle tissue with Triton X-100
eliminates the contraction induced by PKC activation, and the addition of recombinant CPI-17 restores PKCmediated contraction (38). The extent of smooth muscle contraction evoked by phorbol ester stimulation
depends on the CPI-17 expression level (35). Interestingly, CPI-17 is absent in tissues from the American farm
chicken, and as such provides an excellent model of CPI-17-null smooth muscle (39). Stimulation with
agonists, PDBu, or G-proteins evokes a marginal extent of the contraction of chicken aortic smooth muscle,
suggesting the importance of CPI-17 in agonist-induced smooth muscle contraction (39). Furthermore,
fluctuations in CPI-17 signals reportedly occur under pathological conditions, such as hypertension, asthma,
inflammation, and diabetes (40-45). For example, CPI-17 expression and phosphorylation are up-regulated in
hypoxia-induced pulmonary hypertension (40). CPI-17 up-regulation is also found in airway smooth muscle
during inflammation and in diabetic bladder smooth muscle (41,45). In contrast, inflammation causes downregulation of CPI-17 in intestinal smooth muscle in parallel with a reduction in muscle tone (43). How
inflammatory signals trigger this bi-directional regulation of CPI-17 in different smooth muscle tissues remains
unknown.
CPI-17 in other cell types: Reversible phosphorylation of myosin is involved in controlling endothelial cell
motility and platelet activation. CPI-17 in endothelial cells and platelets translates the activation of PKC and/or
ROCK into MLCP inhibition and myosin-II phosphorylation as seen in smooth muscle (46,47). In Purkinje
neurons, CPI-17 is involved in long-term synaptic depression (37). The synaptic depression of cerebellar
Purkinje cells occurs through PKC-mediated chronic internalization of the AMPA receptor in response to
glutamate release. Neutralization of endogenous CPI-17 in Purkinje cells using siRNA or a blocking antibody
results in rapid recovery of membrane current upon glutamate stimulation (37), suggesting that metabotropic
Glu receptor-induced activation of PKC causes CPI-17 phosphorylation and subsequent MLCP inhibition, thus
maintaining AMPA receptor internalization (37). Furthermore, CPI-17 drives cell proliferation by activating the
MAP kinase signal pathway (48). Growth factor signals induce phosphorylation of merlin, a product of the
neurofibromatosis type-2 gene, which relieves inhibition of the ERK1/2 signal. Merlin is phosphorylated by a
subset of protein kinases, including ROCK, PAK and PKC, which are also capable of phosphorylating CPI-17.
Overexpression of CPI-17 down- and up-regulates MLCP and merlin phosphorylation, respectively, and
attenuates the tumor-suppression activity of merlin (48,49). Over 90 % of cancer cells are derived from
epithelial cells, where trace amounts of CPI-17 are expressed (35,36). The role of CPI-17 in normal epithelium
remains to be investigated.
Functions of other CPI-17 family members
PHI: Both PHI-1 and -2 are products of the phospholipase C-neighboring gene (PNG, PPP1R14B) (50). PNG
was originally discovered on chromosome 11 as a candidate gene involved in multiple endocrine neoplasia type
1, although later studies eliminated that possibility. Two potential initiation ATG sequences exist in the PNG
transcript (11,50). Initiation at the first ATG yields a 203-residue polypeptide, named PHI-2, whereas the other
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in-frame ATG initiates translation for the 147-residue PHI-1 (Fig. 1A, red triangle) (11). PHI-1 is ubiquitously
and abundantly expressed in various tissues and cultured cells. In contrast, PHI-2 expression is restricted to
muscle tissues (11). Immunohistochemical analysis showed a significant difference between CPI-17 and PHI1/2 localization, with the antibody recognizing both PHI-1 and PHI-2 heavily staining skeletal muscle capillary
endothelium and the juxtamembrane region of the ileac smooth muscle layer (51). Recombinant PHI-1 inhibits
PP1 and the purified MLCP complex upon phosphorylation at Thr57 (11). Phosphorylated PHI-1 evokes
contraction of skinned smooth muscle strips (52). However, the inhibitory potency of PHI-1 for the MLCP
complex (IC50 = 50 nM) is significantly lower compared to CPI-17 (IC50 = 1 nM), suggesting novel target PP1
holoenzymes for PHI-1. Purified PKC and ROCK are capable of phosphorylating PHI-1 at Thr57 and other
undetermined site(s) (52), whereas ILK exclusively phosphorylates PHI-1 at Thr57 (52). Activation of Gproteins in smooth muscle tissues induces the phosphorylation of endogenous PHI-1 (53,54). On the other hand,
reconstitution of unphosphorylated PHI-1 does not restore phorbol ester-induced contraction of CPI-17-null
chicken smooth muscle (39). Therefore, PHI-1 is not involved in PKC-mediated MLCP inhibition. The
endothelial expression of PHI-1 is involved in cell migration (55). Endogenous PHI-1 accumulates at the
leading edge of endothelial cells, and gene silencing of PHI-1 can retard cell migration. Interestingly, PHI-1
knockdown does not affect the phosphorylation status of MLCP-substrate proteins, such as myosin light chain
and ezrin/radixin/moesin (55), suggesting that PHI-1 controls a novel subset of PP1 holoenzymes in endothelial
cells.
KEPI and GBPI: KEPI (PPP1R14C, chromosome 6) was discovered as a protein that is up-regulated in brain
tissue isolated from morphine-addicted mice (12). In terms of amino acid sequence KEPI seems to be more
closely related to PHI-1 than CPI-17. The phosphorylation of KEPI at Thr75 by PKC is sufficient to convert this
protein into a potent PP1 inhibitor (12). A PP1-binding motif (-KVFF-) exists in the N-terminal tail of KEPI
(Fig. 1A, green box). Indeed, PP1 co-precipitates with beads conjugated with unphosphorylated KEPI (56).
Purified PKC and ILK phosphorylates recombinant KEPI at Thr73, the inhibitory phosphorylation site (12,57).
Phospho-KEPI inhibits the purified MLCP complex and isolated PP1 with an IC50 of 8 nM and 0.1 nM,
respectively (57). Therefore, phospho-KEPI potently inhibits the PP1 holoenzyme, but the N-terminal KVFF
sequence of KEPI may affect its inhibitory potency. Recently, KEPI was re-discovered in a group of genes that
are down-regulated in breast tumor cells, along with a known tumor suppressor, phosphatase and tensin
homolog (PTEN) (58). Ectopic expression of KEPI in MCF7 cells induces up-regulation of PTEN via
augmentation of ERK1/2 phosphorylation. Interestingly, although both CPI-17 and KEPI are involved in
ERK1/2 phosphorylation, there is a clear contrast in their downstream signals (48,58), suggesting different pools
of target PP1 holoenzymes may exist for each inhibitor. GBPI (PPP1R14D, chromosome 15) was discovered as
a homologue of KEPI (13). The gene transcribes two splicing variants, GBPI and GBPI-2 (Fig. 1A). GBPI
includes an intact PHIN domain whose sequence is 35 % identical to CPI-17. On the other hand, the testisspecific GBPI-2 mRNA includes a frameshift at the A-B loop, and as such is unlikely to inhibit PP1. GBPI
phosphorylated by PKC inhibits isolated PP1 with an IC50 value of 3 nM. Phosphorylation of GBPI with PKA
eliminates its inhibitory potency. A PP1-binding motif, KVHW, is found in the N-terminal tail (Fig. 1A, green
box), which is necessary for the inhibition of the isolated PP1 catalytic subunit (13). Whether GBPI is capable of
inhibiting PP1 holoenzymes has yet to be tested. Interestingly, GBPI enhances PP2A activity following its
phosphorylation by PKC (13).
Cellular regulation of PP1 holoenzymes via PP1 inhibitor proteins
After the discovery of CPI-17 and CPI-17 family members, it becomes clear that PP1 inhibitor proteins
characterized previously also engage in the control of cellular PP1 holoenzymes in the absence of subunit
dissociation. For example, PP1 inhibitor-2 (I-2) inhibits a complex of PP1 and a microtubule-binding kinase,
Nek2 through the conserved C-terminal domain of I-2 (59), which directly docks at the active site of PP1 in the
co-crystal model of the PP1•I-2 complex (60). In addition, PP1 inhibitor-1 and inhibitor-3 also inhibit PP1
holoenzymes (reviewed in (3)). Thus, each PP1 inhibitor protein may target a specific subset of PP1
holoenzymes, and there are more PP1 inhibitor proteins that transduce kinase signals into phosphatases, as over
100 polypeptides function as PP1 regulatory subunits. A proteomic approach (“PP1 inhibitome”) will be useful
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to gain a full understanding of the specific combinations of kinases, PP1 holoenzymes and inhibitor proteins. As
discussed here, CPI-17 as well as other PP1 inhibitor proteins plays vital roles in signal transduction controlling
both amplitude and duration of phosphorylation. Additional PP1 inhibitor proteins will surely be re-discovered
as disease-causing genes, and recognized as novel therapeutic targets.
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Figure Legend
Fig. 1: CPI-17 family. (A) Schematic illustration of the CPI-17 family primary structure. The inhibitory
phosphorylation site (red) is located in the conserved PP1 holoenzyme inhibitory (PHIN) domain (cyan box).
Gray dots and green boxes indicate additional phosphorylation sites and PP1 binding motifs, respectively. (B)
Electrostatic surface potential map of the CPI-17 family. The surface model of phospho-CPI-17 was used as a
template, and putative models for other proteins were generated in-silico based on the sequence alignment. The
surface modeling was performed by Altif Laboratories (Tokyo, Japan).
Fig. 2: A model for selective inhibition of MLCP by phospho-CPI-17. Upon phosphorylation of Thr38, CPI-17
undergoes a conformational change that results in a re-alignment of the four helices A-D (middle). PhosphoCPI-17 docks at the active site of MLCP and suppresses its activity (right). Other PP1 holoenzymes can
dephosphorylate phospho-CPI-17 and neutralize its inhibitory potency.
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